NeoPharm CO. LTD
NeoPharm CO., LTD. manufactures and sells skin care products in South Korea. The company offers Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand; products for sensitive, dry, oily, or trouble-prone skin under the ZEROID brand; body moisturizers under the Derma-B brand; and sport care products for athletes under the MISSION ATHELE… Read more
Market Cap & Net Worth: NeoPharm CO. LTD (092730)
NeoPharm CO. LTD (KQ:092730) has a market capitalization of $96.52 Million (₩141.32 Billion) as of March 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #20692 globally and #919 in its home market, demonstrating a 3.09% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NeoPharm CO. LTD's stock price ₩17690.00 by its total outstanding shares 7988700 (7.99 Million).
NeoPharm CO. LTD Market Cap History: 2015 to 2026
NeoPharm CO. LTD's market capitalization history from 2015 to 2026. Data shows growth from $79.75 Million to $96.52 Million (1.84% CAGR).
Index Memberships
NeoPharm CO. LTD is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.03% | #416 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.03% | #416 of 1384 |
Weight: NeoPharm CO. LTD's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
NeoPharm CO. LTD Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NeoPharm CO. LTD's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
NeoPharm CO. LTD's market cap is 0.00 times its annual revenue
0.00x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.00x
NeoPharm CO. LTD's market cap is 0.00 times its annual earnings
0.02x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $79.75 Million | $35.96 Billion | $3.41 Billion | 0.00x | 0.02x |
| 2016 | $60.80 Million | $42.37 Billion | $7.74 Billion | 0.00x | 0.01x |
| 2017 | $111.08 Million | $53.63 Billion | $11.56 Billion | 0.00x | 0.01x |
| 2018 | $107.57 Million | $66.27 Billion | $15.37 Billion | 0.00x | 0.01x |
| 2019 | $117.44 Million | $83.24 Billion | $19.25 Billion | 0.00x | 0.01x |
| 2020 | $70.95 Million | $81.63 Billion | $18.13 Billion | 0.00x | 0.00x |
| 2021 | $63.38 Million | $87.93 Billion | $17.71 Billion | 0.00x | 0.00x |
| 2022 | $50.85 Million | $85.03 Billion | $17.03 Billion | 0.00x | 0.00x |
| 2023 | $70.52 Million | $97.10 Billion | $23.21 Billion | 0.00x | 0.00x |
| 2024 | $64.65 Million | $119.01 Billion | $23.06 Billion | 0.00x | 0.00x |
Competitor Companies of 092730 by Market Capitalization
Companies near NeoPharm CO. LTD in the global market cap rankings as of March 19, 2026.
Key companies related to NeoPharm CO. LTD by market ranking:
- HYUNDAI BIOLAND Co.Ltd (KQ:052260): Ranked #24084 globally with a market cap of $27.04 Million USD ( ₩39.59 Billion KRW).
- Globon Co. Ltd (KQ:019660): Ranked #24425 globally with a market cap of $25.19 Million USD ( ₩36.88 Billion KRW).
- Gentrogroup Co. Ltd. (KQ:083660): Ranked #32008 globally with a market cap of $4.07 Million USD ( ₩5.96 Billion KRW).
- Nextbike Polska SA (WAR:NXB): Ranked #43044 globally with a market cap of $32.21K USD ( zł133.93K PLN).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #24084 | HYUNDAI BIOLAND Co.Ltd | KQ:052260 | $27.04 Million | ₩4060.00 |
| #24425 | Globon Co. Ltd | KQ:019660 | $25.19 Million | ₩2440.00 |
| #32008 | Gentrogroup Co. Ltd. | KQ:083660 | $4.07 Million | ₩289.00 |
| #43044 | Nextbike Polska SA | WAR:NXB | $32.21K | zł14.30 |
NeoPharm CO. LTD Historical Marketcap From 2015 to 2026
Between 2015 and today, NeoPharm CO. LTD's market cap moved from $79.75 Million to $ 96.52 Million, with a yearly change of 1.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩96.52 Million | -3.70% |
| 2025 | ₩100.23 Million | +55.02% |
| 2024 | ₩64.65 Million | -8.32% |
| 2023 | ₩70.52 Million | +38.67% |
| 2022 | ₩50.85 Million | -19.77% |
| 2021 | ₩63.38 Million | -10.67% |
| 2020 | ₩70.95 Million | -39.59% |
| 2019 | ₩117.44 Million | +9.18% |
| 2018 | ₩107.57 Million | -3.16% |
| 2017 | ₩111.08 Million | +82.69% |
| 2016 | ₩60.80 Million | -23.76% |
| 2015 | ₩79.75 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of NeoPharm CO. LTD was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $96.52 Million USD |
| MoneyControl | $96.52 Million USD |
| MarketWatch | $96.52 Million USD |
| marketcap.company | $96.52 Million USD |
| Reuters | $96.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.